Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amgen
(NQ:
AMGN
)
261.01
-5.30 (-1.99%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 3, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,792,150
Open
264.04
Bid (Size)
260.08 (2)
Ask (Size)
261.50 (1)
Prev. Close
266.31
Today's Range
259.67 - 266.02
52wk Range
218.44 - 296.67
Shares Outstanding
N/A
Dividend Yield
3.26%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Is Amgen's Lung Cancer Drug Lumakras Up to the Mark? FDA Briefing Raises Concerns
Today 15:30 EDT
The FDA released briefing documents ahead of Oncologic Drugs Advisory Committee meeting scheduled for October 5 to review Amgen Inc's (NASDAQ:
Via
Benzinga
Exposures
Product Safety
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
Today 13:35 EDT
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration
Via
Benzinga
Performance
YTD
-0.24%
-0.24%
1 Month
+2.76%
+2.76%
3 Month
+16.00%
+16.00%
6 Month
+6.78%
+6.78%
1 Year
+13.27%
+13.27%
More News
Read More
Check Out What Whales Are Doing With AMGN
September 29, 2023
Via
Benzinga
AskSlim Market Week - Friday, Sep. 29
September 29, 2023
Via
Talk Markets
3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
September 28, 2023
Via
InvestorPlace
2 Dividend Growth Stocks to Buy Right Now
September 21, 2023
Via
The Motley Fool
Check Out What Whales Are Doing With AMGN
September 20, 2023
Via
Benzinga
Amgen Unusual Options Activity
September 15, 2023
Via
Benzinga
September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average
September 27, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients
September 25, 2023
Via
Benzinga
Exposures
Product Safety
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Via
MarketBeat
AI To Revolutionize Clinical Trials And Diagnostics
September 22, 2023
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
$1000 Invested In This Stock 15 Years Ago Would Be Worth $4,200 Today
September 13, 2023
Via
Benzinga
2 Top Dividend Stocks to Buy in September
September 13, 2023
Via
The Motley Fool
How Is The Market Feeling About Amgen?
September 08, 2023
Via
Benzinga
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
September 22, 2023
Via
FinancialNewsMedia
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
September 22, 2023
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Why Shares of Neumora Therapeutics Slumped This Week
September 21, 2023
Via
The Motley Fool
Topics
Initial Public Offering
Exposures
Securities Market
Flee to Healthcare Stocks if Recession Rears its Head?
September 20, 2023
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
3 Quality Dividend Stocks For A Bear Market
September 14, 2023
Via
Talk Markets
Topics
Economy
Exposures
Economy
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
September 13, 2023
Via
Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in September 2023
September 12, 2023
Via
InvestorPlace
Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis
September 11, 2023
Via
Benzinga
Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
September 11, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
September 06, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.